Cytokinetics Inc. - CYTK STOCK NEWS

Cytokinetics granted stock options for 88,200 shares to 11 new employees as an inducement to employment on July 29, 2022. The exercise price is set at $42.33 per share, equivalent to the stock's closing price on that date. These options will vest over four years, with one-quarter vesting on the first anniversary and the rest monthly. This action complies with Nasdaq Listing Rule 5635(c)(4). Cytokinetics focuses on developing innovative treatments for muscle performance-related diseases.

Cytokinetics, Incorporated (Nasdaq: CYTK) will announce its second quarter results on August 4, 2022, at 4:00 PM ET, followed by a management conference call at 4:30 PM ET. This call will cover operational and financial results, along with the company's future outlook. Interested parties can access the call via the company's website. Cytokinetics focuses on developing innovative muscle activators and inhibitors for conditions affecting muscle performance. Notably, it is preparing for the commercialization of omecamtiv mecarbil after a successful Phase 3 trial in heart failure patients.

Cytokinetics, Incorporated (Nasdaq: CYTK) announced the granting of stock options for 180,450 shares to 19 new employees as of June 30, 2022. The options have an exercise price of $39.29, equal to the closing stock price on that date. They will vest over four years, with 25% vesting after one year. This move is designed as a material inducement for employment, in line with Nasdaq Listing Rule 5635(c)(4). Cytokinetics is focused on developing innovative muscle-targeted therapies for serious conditions.

Cytokinetics (Nasdaq: CYTK) announced a $450 million offering of 3.50% convertible senior notes due 2027, with a 30% conversion premium. This follows a repurchase of $116.9 million of 4.00% notes due 2026. The notes will accrue interest semi-annually and are scheduled to settle on July 6, 2022. Proceeds will be used for clinical development programs and general corporate purposes. Additionally, Cytokinetics increased required term loans with Royalty Pharma from $25 million to $50 million. The offering is not registered under the Securities Act, limiting market sales.

Cytokinetics plans to offer $450 million in convertible senior notes due 2027 in a private offering, with an option for an additional $90 million. The notes will be senior, unsecured obligations accruing interest semi-annually and maturing on July 1, 2027. Proceeds will fund clinical development for aficamten in hypertrophic cardiomyopathy and support commercial capabilities for omecamtiv mecarbil and aficamten. A part of the proceeds will also repurchase existing convertible notes due 2026. The offering is subject to market conditions and will not be registered under the Securities Act.

Cytokinetics announced that the FDA will review its New Drug Application for omecamtiv mecarbil during a meeting on December 13, 2022. This investigational drug aims to treat heart failure with reduced ejection fraction (HFrEF). The FDA's PDUFA target action date is set for February 28, 2023. The drug has shown positive results in the GALACTIC-HF clinical trial, significantly reducing cardiovascular deaths and heart failure events. Cytokinetics is preparing for potential commercialization following this approval process.

Cytokinetics has announced an extension of the PDUFA date for its new drug application (NDA) for omecamtiv mecarbil by three months to February 28, 2023, in response to a request from the FDA for additional pharmacokinetic analyses. The drug aims to treat worsening heart failure and has shown positive results in the GALACTIC-HF trial. The company remains committed to bringing this first-in-class cardiac myosin activator to market.

Cytokinetics has announced the initiation of COURAGE-ALS OLE, an open-label extension study for the investigational drug reldesemtiv, aimed at assessing long-term safety in ALS patients. Participants from the previous COURAGE-ALS trial are eligible, continuing with a dosage of 300 mg twice daily for 48 weeks. The primary focus will be on adverse event incidence and secondary endpoints including respiratory insufficiency and survival time. Additionally, a Managed Access Program will be launched for earlier trial participants later this year.

Cytokinetics presented new echocardiographic data at the ASE Annual Scientific Sessions, highlighting the positive effects of aficamten in treating obstructive hypertrophic cardiomyopathy (HCM). In a study involving 41 patients, significant improvements were observed in cardiac structure and function after 10 weeks of treatment. Key findings include a reduction in left atrial volume index (p<0.01) and improved mitral valve dynamics, with the proportion of patients experiencing systolic anterior motion (SAM) decreasing from 85.7% to 35.7% (p=0.038). The findings suggest notable early signs of enhanced cardiac health.